Chengdu Suncadia Medicine Co., Ltd.
Clinical trials sponsored by Chengdu Suncadia Medicine Co., Ltd., explained in plain language.
-
New drug HRS-1635 enters early human testing for hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests the safety and tolerability of a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. Researchers will find the best dose and watch for side effects. The goal is to control the disease, no…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Not yet recruitingThis study tests the long-term safety of HRS-5965 capsules in 380 adults with primary IgA nephropathy, a kidney disease. Participants will take the drug and be monitored for side effects, as well as changes in urine protein and kidney function. The goal is to see if HRS-5965 can …
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug HRS-3095 aims to soothe stubborn hives
Symptom relief Not yet recruitingThis Phase 2 trial tests whether the experimental drug HRS-3095 can reduce itching and wheals in adults with chronic spontaneous urticaria (hives) that isn't well controlled by antihistamines. About 190 participants will receive either the drug or a placebo daily for 4 weeks. The…
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC